Local Analgesic Reduces Post-Bariatric Opioids
Study explores Exparel's use in managing abdominal surgery pain.
Published: February 3, 2014
A multimodal pain management therapy that includes the non-opioid local analgesic Exparel lessens the need for post-op narcotics after bariatric surgery, according to a recent study.
For the study, Andras Sandor, MD, FACS, FASMBS, and colleagues at the Hallmark Health Center for Weight Management and Weight Loss Surgery in Medford, Mass., observed the pain management regimens of 90 patients undergoing laparoscopic bariatric procedures.
Half of the patients received a multimodal approach to post-op pain management, including Pacira Pharmaceutical's bupivacaine liposome injectable suspension drug, Exparel, infiltrated into the transversus abdominis plane (a process known as iTAP). The other half were given ketorolac and a lidocaine and bupivacaine/epinephrine combination perioperatively, and pain pumps of hydromorphone afterward.
Each group was allowed opioids at 2 days post-op. But the multimodal group consumed 60.7% fewer opioids. Additionally, they exhibited a greater return of bowel function at the 2-day mark. Dr. Sandor and his team presented their findings at the American Society for Metabolic & Bariatric Surgery's 2013 Obesity Week in November.
"The risks of opioids are pronounced in the bariatric population; utilizing a non-opioid platform with Exparel iTAP at its foundation contributed to decreasing both the amount of opioids needed and their resultant opioid-related adverse effects," says Dr. Sandor.
© Copyright Herrin Publishing Partners LP. REPRODUCTION OF THIS COPYRIGHTED CONTENT IS STRICTLY PROHIBITED. We encourage LINKING to this content; view our linking policy here.
Also in the News...
Surgeon Operated on Wrong Part of Brain
Widow Sues Olympus and Custom Ultrasonics Over Husband's Superbug Death
Surgeons Reach Peak Performance Between 35 and 50 Years Old
Results From Head-to-Head Comparison of Exparel and Conventional Bupivacaine
Forbes: Punitive Ban on Physician-Owned Hospitals Imposed by the Affordable Care Act Has to Go
'Post-Hospital Syndrome' Is a Risk Factor in Elective Surgery
FDA Approval of Sugammadex Appears Imminent